Gregory G Westin1, Ehrin J Armstrong2, Heejung Bang3, Khung-Keong Yeo2, David Anderson1, David L Dawson4, William C Pevec4, Ezra A Amsterdam2, John R Laird5. 1. School of Medicine and the Vascular Center, UC Davis Medical Center, Sacramento, California. 2. Division of Cardiovascular Medicine and the Vascular Center, UC Davis Medical Center, Sacramento, California. 3. Division of Biostatistics, Department of Public Health Sciences, UC Davis, Davis, California. 4. Division of Vascular and Endovascular Surgery, the Vascular Center, Sacramento, California. 5. Division of Cardiovascular Medicine and the Vascular Center, UC Davis Medical Center, Sacramento, California. Electronic address: john.laird@ucdmc.ucdavis.edu.
Abstract
OBJECTIVES: The aim of this study was to determine the associations between statin use and major adverse cardiovascular and cerebrovascular events (MACCE) and amputation-free survival in critical limb ischemia (CLI) patients. BACKGROUND: CLI is an advanced form of peripheral arterial disease associated with nonhealing arterial ulcers and high rates of MACCE and major amputation. Although statin medications are recommended for secondary prevention in peripheral arterial disease, their effectiveness in CLI is uncertain. METHODS: We reviewed 380 CLI patients who underwent diagnostic angiography or therapeutic endovascular intervention from 2006 through 2012. Propensity scores and inverse probability of treatment weighting were used to adjust for baseline differences between patients taking and not taking statins. RESULTS: Statins were prescribed for 246 (65%) patients. The mean serum low-density lipoprotein (LDL) level was lower in patients prescribed statins (75 ± 28 mg/dl vs. 96 ± 40 mg/dl, p < 0.001). Patients prescribed statins had more baseline comorbidities including diabetes, coronary artery disease, and hypertension, as well as more extensive lower extremity disease (all p values <0.05). After propensity weighting, statin therapy was associated with lower 1-year rates of MACCE (stroke, myocardial infarction, or death; hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.28 to 0.99), mortality (HR: 0.49, 95% CI: 0.24 to 0.97), and major amputation or death (HR: 0.53, 95% CI: 0.35 to 0.98). Statin use was also associated with improved lesion patency among patients undergoing infrapopliteal angioplasty. Patients with LDL levels >130 mg/dl had increased HRs of MACCE and mortality compared with patients with lower levels of LDL. CONCLUSIONS: Statins are associated with lower rates of mortality and MACCE and increased amputation-free survival in CLI patients.
OBJECTIVES: The aim of this study was to determine the associations between statin use and major adverse cardiovascular and cerebrovascular events (MACCE) and amputation-free survival in critical limb ischemia (CLI) patients. BACKGROUND: CLI is an advanced form of peripheral arterial disease associated with nonhealing arterial ulcers and high rates of MACCE and major amputation. Although statin medications are recommended for secondary prevention in peripheral arterial disease, their effectiveness in CLI is uncertain. METHODS: We reviewed 380 CLI patients who underwent diagnostic angiography or therapeutic endovascular intervention from 2006 through 2012. Propensity scores and inverse probability of treatment weighting were used to adjust for baseline differences between patients taking and not taking statins. RESULTS: Statins were prescribed for 246 (65%) patients. The mean serum low-density lipoprotein (LDL) level was lower in patients prescribed statins (75 ± 28 mg/dl vs. 96 ± 40 mg/dl, p < 0.001). Patients prescribed statins had more baseline comorbidities including diabetes, coronary artery disease, and hypertension, as well as more extensive lower extremity disease (all p values <0.05). After propensity weighting, statin therapy was associated with lower 1-year rates of MACCE (stroke, myocardial infarction, or death; hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.28 to 0.99), mortality (HR: 0.49, 95% CI: 0.24 to 0.97), and major amputation or death (HR: 0.53, 95% CI: 0.35 to 0.98). Statin use was also associated with improved lesion patency among patients undergoing infrapopliteal angioplasty. Patients with LDL levels >130 mg/dl had increased HRs of MACCE and mortality compared with patients with lower levels of LDL. CONCLUSIONS: Statins are associated with lower rates of mortality and MACCE and increased amputation-free survival in CLI patients.
Authors: Jeffrey W Olin; David E Allie; Michael Belkin; Robert O Bonow; Donald E Casey; Mark A Creager; Thomas C Gerber; Alan T Hirsch; Michael R Jaff; John A Kaufman; Curtis A Lewis; Edward T Martin; Louis G Martin; Peter Sheehan; Kerry J Stewart; Diane Treat-Jacobson; Christopher J White; Zhi-Jie Zheng; Frederick A Masoudi Journal: Circulation Date: 2010-11-29 Impact factor: 29.690
Authors: Caroline E McCoach; Ehrin J Armstrong; Satinder Singh; Usman Javed; David Anderson; Khung Keong Yeo; Gregory G Westin; Nasim Hedayati; Ezra A Amsterdam; John R Laird Journal: Vasc Med Date: 2013-02 Impact factor: 3.239
Authors: Nathan Fernandez; Ryan McEnaney; Luke K Marone; Robert Y Rhee; Steven Leers; Michel Makaroun; Rabih A Chaer Journal: J Vasc Surg Date: 2010-10 Impact factor: 4.268
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Ali F AbuRahma; Mohit Srivastava; Patrick A Stone; Bryan K Richmond; Zachary AbuRahma; Will Jackson; L Scott Dean; Albeir Y Mousa Journal: J Am Coll Surg Date: 2014-12-15 Impact factor: 6.113
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen Journal: Clin Cardiol Date: 2018-10-19 Impact factor: 2.882
Authors: Benjamin S B Rasmussen; Knud B Yderstraede; Bendix Carstensen; Ole Skov; Henning Beck-Nielsen Journal: Diabetologia Date: 2015-11-22 Impact factor: 10.122
Authors: Gregory G Westin; Ehrin J Armstrong; Usman Javed; Christopher R Balwanz; Haseeb Saeed; William C Pevec; John R Laird; David L Dawson Journal: Ann Vasc Surg Date: 2014-08-06 Impact factor: 1.466